COCH · XBRL financial data

Envoy Medical financial statements, every fiscal year

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (COCH's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	—	237	316	225	241
Cost of revenue	—	—	789	742	—
Cost of goods and services sold	—	498	789	742	874
Research and development	—	4,975	8,956	10,179	12,486
Selling, general and administrative	—	2,585	7,276	—	—
General and administrative	—	—	1,356	6,826	7,931
Operating income (loss)	(5,205)	(4,888)	(18,371)	(19,256)	(22,270)
Interest income	38	6,125	—	—	—
Interest expense	—	—	—	816	1,590
Other income (expense)	—	(127)	80	(26)	(23)
Income tax expense (benefit)	—	1,502	—	—	—
Net income (loss)	(252)	19,234	(29,908)	(20,795)	(23,756)
Earnings per share, basic USD per share	—	(1.57)	(2.38)	(1.49)	(1.23)
Earnings per share, diluted USD per share	—	(1.57)	(2.38)	(1.49)	(1.23)
Weighted average shares, basic thousands of shares	—	10,123	12,553	18,790	23,260
Weighted average shares, diluted thousands of shares	—	10,123	12,553	18,790	23,260

Fiscal years (COCH's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	150	108	4,218	5,483	3,739
Accounts receivable	—	41	70	38	34
Inventory	—	1,295	1,404	1,708	1,546
Prepaid and other current assets	—	129	957	1,375	941
Total current assets	863	220	6,825	9,384	6,279
Property and equipment, net	—	331	351	1,275	1,035
Total assets	426,904	430,621	7,640	11,538	8,558
Accounts payable	619	1,178	1,554	1,652	2,920
Accrued liabilities	2,059	3,946	4,613	4,416	7,639
Total current liabilities	2,678	7,310	6,636	7,538	11,562
Total liabilities	38,617	18,789	9,402	30,380	20,325
Accumulated deficit	(36,715)	(17,916)	(257,242)	(284,734)	(313,396)
Total stockholders' equity	(36,714)	(17,915)	(1,762)	(18,842)	(12,158)
Total liabilities and equity	426,904	430,621	7,640	11,538	8,558
Common shares outstanding (cover page) thousands of shares	—	—	19,600	21,327	76,881

Fiscal years (COCH's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(252)	19,234	(29,908)	(20,795)	(23,756)
Stock-based compensation	—	—	1,575	562	657
Net cash from operating activities	(3,241)	(2,658)	(17,654)	(17,949)	(18,201)
Purchases of property and equipment	—	218	153	980	179
Net cash from investing activities	(425,000)	1,116	(153)	(980)	(179)
Proceeds from issuing common stock	—	—	109	—	414
Dividends paid	—	—	—	2,447	1,819
Net cash from financing activities	428,366	1,500	21,845	20,198	16,633
Net change in cash	125	(42)	4,035	1,265	(1,744)

SIC 3842 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3842 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Envoy Medical	19,679	51	(5,456)*	77.2M	3.6 quarters	Q2 FY26 10-QJun 30, 2026
VASO	38,291	not reported	17,444*	176.0M	—	Q2 FY26 10-QJun 30, 2026
PetVivo Holdings	123	338	(966)	38.0M	0.1 quarters	Q1 FY27 10-QJun 30, 2026
Biotricity	467	4,277	507	19.9M	—	Q1 FY27 10-QJun 30, 2026
PAVmed	3,784	33	(2,663)*	8.0M	1.4 quarters	Q2 FY26 10-QJun 30, 2026
Intelligent Bio Solutions	3,992	1,146*	(3,182)*	3.0M	1.3 quarters	Q4 FY26 10-KJun 30, 2026
Iridex	4,680	12,566	174*	17.6M	—	Q2 FY26 10-QJul 4, 2026
Lyra Therapeutics	15,893	7*	(6,066)*	1.8M	2.6 quarters	Q4 FY25 10-KDec 31, 2025
Nexgel	1,706	3,686	(2,197)*	9.7M	0.8 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.